Protein expression and methylation of DNA repair genes hMLH1, hMSH2, MGMT and BRCA1 and their correlation with clinicopathological parameters and prognosis in basal-like breast cancer

Histopathology

Volumn 63, Issue 5, 2013, Pages 713-725

  Alkam, Yimit ^a   Mitomi, Hiroyuki ^b   Nakai, Katsuya ^a   Himuro, Takanori ^a   Saito, Tsuyoshi ^a   Takahashi, Michiko ^a   Arakawa, Atsushi ^a   Yao, Takashi ^a   Saito, Mitsue ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Basal like subtype; Breast cancer; DNA repair gene; P53; Promoter methylation

Indexed keywords

BRCA1 PROTEIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN MLH1; PROTEIN MSH2; PROTEIN P53;

ADULT; AGED; ARTICLE; BASAL LIKE BREAST CANCER; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DNA METHYLATION; DNA REPAIR; FEMALE; GENE SEQUENCE; GENETIC CORRELATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME;

BASAL-LIKE SUBTYPE; BREAST CANCER; DNA REPAIR GENE; P53; PROMOTER METHYLATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; BRCA1 PROTEIN; BREAST NEOPLASMS; CARCINOMA, BASAL CELL; DISEASE PROGRESSION; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA MUTATIONAL ANALYSIS; DNA REPAIR ENZYMES; FEMALE; HUMANS; MIDDLE AGED; MUTS HOMOLOG 2 PROTEIN; NUCLEAR PROTEINS; PROGNOSIS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEINS;

EID: 84885431188     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12220     Document Type: Article

References (32)

1. Perou CM, Sørlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406; 747-752.
2. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 2004; 10; 5367-5374.
3. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum. Pathol. 2006; 37; 1217-1226.
4. Banerjee S, Reis-Filho JS, Ashley S et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J. Clin. Pathol. 2006; 59; 729-735.
5. Manieé E, Vincent-Salomon A, Lehmann-Che J et al. High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res. 2009; 69; 663-671.
6. Neto JC, Ikoma MM, Carvalho KC et al. MGMT and PTEN as potential prognostic markers in breast cancer. Exp. Mol. Pathol. 2012; 92; 20-26.
7. Turner NC, Reis-Filho JS, Russell AM et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007; 26; 2126-2132.
8. Xu X, Gammon MD, Zhang Y et al. BRCA1 promoter methylation is associated with increased mortality among women with breast cancer. Breast Cancer Res. Treat. 2009; 115; 397-404.
9. Moynahan ME, Chiu JW, Koller BH, Jasin M. BRCA1 controls homology-directed DNA repair. Mol. Cell 1999; 4; 511-518.
10. Jiricny J. The multifaceted mismatch-repair system. Nat. Rev. Mol. Cell Biol. 2006; 7; 335-346.
11. Pegg AE. Repair of O(6)-alkylguanine by alkyl-transferases. Mutat. Res. 2000; 462; 83-100.
12. Murata H, Khattar NH, Kang Y, Gu L, Li GM. Genetic and epigenetic modification of mismatch repair genes hMSH2 and hMLH1 in sporadic breast cancer with microsatellite instability. Oncogene 2002; 21; 5696-5703.
13. Naqvi RA, Hussain A, Deo SS et al. Hypermethylation analysis of mismatch repair genes (hMLH1 and hMSH2) in locally advanced breast cancers in Indian women. Hum. Pathol. 2008; 39; 672-680.
14. Hegi ME, Sciuscio D, Murat A, Levivier M, Stupp R. Epigenetic deregulation of DNA repair and its potential for therapy. Clin. Cancer Res. 2009; 15; 5026-5031.
15. Murata H, Khattar NH, Gu L, Li GM. Roles of mismatch repair proteins hMSH2 and hMLH1 in the development of sporadic breast cancer. Cancer Lett. 2005; 223; 143-150.
16. Munot K, Bell SM, Lane S, Horgan K, Hanby AM, Speirs V. Pattern of expression of genes linked to epigenetic silencing in human breast cancer. Hum. Pathol. 2006; 37; 989-999.
17. Chintamani, Jha BP, Bhandari V, Bansal A, Saxena S, Bhatnagar D. The expression of mismatched repair genes and their correlation with clinicopathological parameters and response to neo-adjuvant chemotherapy in breast cancer. Int. Semin. Surg. Oncol. 2007; 4; 5.
18. Rakha EA, El-Sheikh SE, Kandil MA, El-Sayed ME, Green AR, Ellis IO. Expression of BRCA1 protein in breast cancer and its prognostic significance. Hum. Pathol. 2008; 39; 857-865.
19. Sharma G, Mirza S, Parshad R et al. Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients. Life Sci. 2010; 87; 83-91.
20. Osanai T, Takagi Y, Toriya Y et al. Inverse correlation between the expression of O6-methylguanine-DNA methyl transferase (MGMT) and p53 in breast cancer. Jpn. J. Clin. Oncol. 2005; 35; 121-125.
21. Köster F, Schröer A, Fischer D, Horn AK, Diedrich K, Friedrich M. Immunohistochemistry of proteins for DNA mismatch repair in correlation to prognostic factors of mammarian cancer. Oncol. Rep. 2007; 17; 1223-1227.
22. Karray-Chouayekh S, Trifa F, Khabir A et al. Clinical significance of epigenetic inactivation of hMLH1 and BRCA1 in Tunisian patients with invasive breast carcinoma. J. Biomed. Biotechnol. 2009; 2009; 369129.
23. Børresen-Dale AL. TP53 and breast cancer. Hum. Mutat. 2003; 21; 292-300.
24. Mackay HJ, Cameron D, Rahilly M et al. Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival. J. Clin. Oncol. 2000; 18; 87-93.
25. Nakai K, Mitomi H, Alkam Y et al. Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 protein expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients. Cancer Chemother. Pharmacol. 2012; 69; 923-930.
26. Fumagalli C, Pruneri G, Possanzini P et al. Methylation of O (6)-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients. Breast Cancer Res. Treat. 2012; 134; 131-137.
27. Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch. Pathol. Lab. Med. 2010; 134; e48-e72.
28. Rhodes A, Jasani B, Anderson E, Dodson AR, Balaton AJ. Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. Am. J. Clin. Pathol. 2002; 118; 408-417.
29. Imamhasan A, Mitomi H, Saito T, Arakawa A, Yao T. Clear cell variant of squamous cell carcinoma originating in the esophagus: report of a case with immunohistochemical and oncogenetic analyses. Pathol. Int. 2012; 62; 137-143.
30. Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat. Rev. Cancer 2004; 4; 296-307.
31. Yanamadala S, Ljungman M. Potential role of MLH1 in the induction of p53 and apoptosis by blocking transcription on damaged DNA templates. Mol. Cancer Res. 2003; 1; 747-754.
32. Warnick CT, Dabbas B, Ford CD, Strait KA. Identification of a p53 response element in the promoter region of the hMSH2 gene required for expression in A2780 ovarian cancer cells. J. Biol. Chem. 2001; 276; 27363-27370.